Next Article in Journal
Overview of External Reference Pricing Systems in Europe
Previous Article in Journal
A Chart Review of Management of Ischemic Stroke Patients in Germany
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
JMAHP
Volume 3
Issue 1
10.3402/jmahp.v3.28760
jmahp-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
Journal of Market Access & Health Policy (JMAHP) is published by MDPI from Volume 12 Issue 1 (2024). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Taylor & Francis.
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

A Review of the Value of Innovation in Inhalers for COPD and Asthma

by
Johann Christian Virchow
1,*,
Cezmi A. Akdis
2,
Josep Darba
3,
Richard Dekhuijzen
4,
Sylvia Hartl
5,
Gisela Kobelt
6,
Albert Roger
7,
Steven Simoens
8,
Mondher Toumi
9,
Ben Woodhouse
10,
Adam Plich
11 and
Saku Torvinen
11
1
Department of Pneumology/Intensive Care Medicine, Zentrum für Innere Medizin/Klinik 1, Universitätsmedizin Rostock, 18057 Rostock, Germany
2
Christine Kühne-Center for Allergy Research and Education (CK-CARE), Swiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, Davos, Switzerland
3
Department of Teoria Econòmica, University of Barcelona, Barcelona, Spain
4
Department of Pulmonary Diseases, Radboud University Medical Centre, Nijmegen, The Netherlands
5
Department of Respiratory and Critical Care, Otto Wagner Hospital, Vienna, Austria
6
European Health Economics, Mulhouse, France
7
Allergy Unit, University Hospital Germans Trias I Pujol, Badalona, Spain
8
Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium
9
Department of Public Health, University of Marseilles, Marseille, France
10
NHS Bolton Clinical Commissioning Group, Bolton, UK
11
EVA Pharmaceuticals Europe B.V., Amsterdam, The Netherlands
 
add Show full affiliation list
 
remove Hide full affiliation list
*
Author to whom correspondence should be addressed.
J. Mark. Access Health Policy 2015, 3(1), 28760; https://doi.org/10.3402/jmahp.v3.28760
Submission received: 4 June 2015 / Revised: 11 August 2015 / Accepted: 12 August 2015 / Published: 16 September 2015

Abstract

Background: Appropriate use of inhaled therapies for asthma and chronic obstructive pulmonary disease (COPD) is critical to ensuring good patient outcomes, efficient use of healthcare resources and limiting the effects of high-morbidity. The appropriate choice of inhaler and active therapy, incorporating patient preferences, can help improve treatment adherence and long-term outcomes. Despite this, many current inhalers are non-intuitive to use, and require extensive training. Methods: In this review, an expert panel considers the evidence for the use of inhaler devices in management of COPD and asthma. The panel also evaluates the value of innovation in inhaler technologies, which optimise the use of existing molecules from a clinical, economic and societal perspective. Conclusions: The panel conclusion is that there remains a substantial unmet need in inhaler technology and that innovation in inhaler devices can provide real-world health benefits to patients. Furthermore, we recommend that these innovations should be supported by healthcare systems through appropriate pricing and reimbursement mechanisms.
Keywords: Asthma; Chronic obstructive pulmonary disease; innovation; patient preference; adherence; patient compliance; metered dose inhaler; dry powder inhaler; medication errors; value Asthma; Chronic obstructive pulmonary disease; innovation; patient preference; adherence; patient compliance; metered dose inhaler; dry powder inhaler; medication errors; value

Share and Cite

MDPI and ACS Style

Virchow, J.C.; Akdis, C.A.; Darba, J.; Dekhuijzen, R.; Hartl, S.; Kobelt, G.; Roger, A.; Simoens, S.; Toumi, M.; Woodhouse, B.; et al. A Review of the Value of Innovation in Inhalers for COPD and Asthma. J. Mark. Access Health Policy 2015, 3, 28760. https://doi.org/10.3402/jmahp.v3.28760

AMA Style

Virchow JC, Akdis CA, Darba J, Dekhuijzen R, Hartl S, Kobelt G, Roger A, Simoens S, Toumi M, Woodhouse B, et al. A Review of the Value of Innovation in Inhalers for COPD and Asthma. Journal of Market Access & Health Policy. 2015; 3(1):28760. https://doi.org/10.3402/jmahp.v3.28760

Chicago/Turabian Style

Virchow, Johann Christian, Cezmi A. Akdis, Josep Darba, Richard Dekhuijzen, Sylvia Hartl, Gisela Kobelt, Albert Roger, Steven Simoens, Mondher Toumi, Ben Woodhouse, and et al. 2015. "A Review of the Value of Innovation in Inhalers for COPD and Asthma" Journal of Market Access & Health Policy 3, no. 1: 28760. https://doi.org/10.3402/jmahp.v3.28760

APA Style

Virchow, J. C., Akdis, C. A., Darba, J., Dekhuijzen, R., Hartl, S., Kobelt, G., Roger, A., Simoens, S., Toumi, M., Woodhouse, B., Plich, A., & Torvinen, S. (2015). A Review of the Value of Innovation in Inhalers for COPD and Asthma. Journal of Market Access & Health Policy, 3(1), 28760. https://doi.org/10.3402/jmahp.v3.28760

Article Metrics

Back to TopTop